IP Library Granted Patent US 10,874,654
Granted Patent B2
US 10,874,654 · App. 16/356,949 · Granted Dec 29, 2020

Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide

Inventor: Louis Habash (Irvine, CA)
A61K31/445
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,654
App. No.
16/356,949
Granted
Dec 29, 2020
Kind
B2
Abstract

Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis pathway using a nitroxide.

Claims (12)

1. A method of increasing expression level of Bcl-2-associated athanogene 5 (Bag5) gene in an individual, comprising:

identifying an individual having a downregulated expression level of the Bag5 gene in neuronal tissue relative to the expression level of Bag5 gene in neuronal tissue of a population of individuals of the same sex and similar age; and

administering to the individual an effective amount of a nitroxide antioxidant, the nitroxide antioxidant selected from the group consisting of 2-ethyl-2,5,5-trimethyl-3-oxazolidine-1-oxyl (OXANO), 2,2,6,6-tetramethylpiperidine-1 oxyl (TEMPO), 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), 4-amino-2,2,6,6-tetramethyl-1-piperidinyloxy (Tempatmine), 3-Aminomethyl-PROXYL, 3-Cyano-PROXYL, 3-Carbamoyl-PROXYL, 3-Carboxy-PROXYL, and 4-Oxo-TEMPO, and

whereby the expression level Bag5 is increased to prevent neuronal cell death in the neuronal tissue.

2. The method of claim 1 , wherein the nitroxide antioxidant is TEMPOL.

3. The method of claim 2 , wherein the individual has been diagnosed with Alzheimer's disease.

4. The method of claim 2 , wherein the individual has been diagnosed with Parkinson's disease.

5. The method of claim 2 , wherein the individual has been diagnosed with Huntington's disease.

6. The method of claim 2 , wherein the individual has been diagnosed with amyotrophic lateral sclerosis.

7. The method of claim 2 , wherein the individual has been diagnosed with spinal ataxis.

8. The method of claim 2 , wherein the individual has been diagnosed with spinocerebellar degenerations.

9. The method of claim 2 , wherein the individual has been diagnosed with an age-related neurodegenerative disease.

Continuity (3)
Continuation 15373239 · Dec 8, 2016
Continuation In Part 15078911 · Mar 23, 2016
Related Publication 20190374523A1 · Dec 12, 2019
Cited By (1)
US 12,208,089